Published in Drug Alcohol Depend on November 27, 2011
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry (2012) 2.87
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend (2014) 1.78
Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci (2014) 1.14
Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci (2013) 1.12
Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology (2013) 1.06
Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med (2013) 0.99
Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug Alcohol Depend (2012) 0.96
Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav (2014) 0.92
A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol (2012) 0.90
Diuretic effects of cannabinoids. J Pharmacol Exp Ther (2012) 0.89
Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. Adolesc Psychiatry (Hilversum) (2013) 0.89
The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci (2013) 0.84
Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci (2017) 0.78
The Directive 2010/63/EU on animal experimentation may skew the conclusions of pharmacological and behavioural studies. Sci Rep (2013) 0.78
The Changing Face of Recreational Drug Use. Cerebrum (2016) 0.77
Neurotoxicity of Synthetic Cannabinoids JWH-081 and JWH-210. Biomol Ther (Seoul) (2015) 0.75
Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. J Anal Toxicol (2014) 0.75
Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants. Front Neurosci (2016) 0.75
Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol (2016) 0.75
Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes. Forensic Sci Int (2016) 0.75
Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats. Drug Alcohol Depend (2017) 0.75
Apparent affinity estimates and reversal of the effects of synthetic cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by rimonabant in rhesus monkeys. J Pharmacol Exp Ther (2017) 0.75
Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int (2009) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
"Spice" girls: synthetic cannabinoid intoxication. J Emerg Med (2010) 2.76
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett (2010) 2.24
A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend (2011) 2.05
Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem (2005) 1.99
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Spice: a never ending story? Forensic Sci Int (2009) 1.96
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem (2005) 1.93
JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol (2010) 1.79
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol (2003) 1.73
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One (2011) 1.69
Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med (2011) 1.55
Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev (1992) 1.45
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
The emergence and analysis of synthetic cannabinoids. Drug Test Anal (2011) 1.22
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett (2005) 1.20
Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend (1995) 1.18
Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol (2009) 1.18
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem (1992) 1.13
CB2 receptor ligands. Mini Rev Med Chem (2005) 1.11
Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J Pharmacol Exp Ther (1999) 1.10
CB1 cannabinoid receptor ligands. Mini Rev Med Chem (2005) 1.06
3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem (2003) 1.06
Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem (2008) 1.00
Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) (1995) 0.95
1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett (2006) 0.95
Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem (1995) 0.95
Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC. Pharmacol Biochem Behav (1993) 0.93
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Bioorg Med Chem Lett (2007) 0.80
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther (2003) 1.93
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem (2005) 1.93
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol (2004) 1.88
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol (2003) 1.73
Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol (2012) 1.64
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest (2003) 1.61
Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab (2007) 1.59
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) (2007) 1.53
Maggot therapy in "lower-extremity hospice" wound care: fewer amputations and more antibiotic-free days. J Am Podiatr Med Assoc (2005) 1.52
Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther (2002) 1.41
CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol (2005) 1.38
Inhibition of tumor angiogenesis by cannabinoids. FASEB J (2003) 1.36
Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) (2006) 1.34
Novelty seeking, incentive salience and acquisition of cocaine self-administration in the rat. Behav Brain Res (2010) 1.31
Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci (2012) 1.27
Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol (2002) 1.26
Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol (2006) 1.24
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood (2002) 1.24
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett (2005) 1.20
Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol (2009) 1.18
Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther (2007) 1.17
Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther (2002) 1.17
Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther (2006) 1.15
Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol (2009) 1.15
Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem (2008) 1.12
Effect of environmental enrichment on escalation of cocaine self-administration in rats. Psychopharmacology (Berl) (2010) 1.11
The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts" J Addict Res Ther (2012) 1.10
Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol (2002) 1.10
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol (2004) 1.10
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist. J Med Chem (2004) 1.09
Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) (2004) 1.08
3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem (2003) 1.06
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2',3'-disubstituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes: epibatidine analogues. J Med Chem (2002) 1.05
Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther (2002) 1.05
The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol (2003) 1.04
2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal alpha4beta2 nAChRs. Mol Pharmacol (2006) 1.04
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett (2006) 1.03
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol (2012) 1.03
Escalation of cocaine intake with extended access in rats: dysregulated addiction or regulated acquisition? Psychopharmacology (Berl) (2012) 1.03
Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. Life Sci (2006) 1.03
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists. J Med Chem (2005) 1.01
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther (2002) 1.01
SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav (2002) 1.01
Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum. Mol Pharmacol (2004) 1.00
Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol (2006) 1.00
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol (2010) 0.98
A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol (2004) 0.98
Synthesis, nicotinic acetylcholine receptor binding, antinociceptive and seizure properties of methyllycaconitine analogs. Bioorg Med Chem (2006) 0.98
Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend (2008) 0.96
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol (2007) 0.96
WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol (2006) 0.96
Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol (2002) 0.96
Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice. Behav Pharmacol (2008) 0.96
Cannabis produces dependence: a comment on Smith. Addiction (2002) 0.96
Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids (2002) 0.95
Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology (2009) 0.95
1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett (2006) 0.95
Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs. Bioorg Med Chem (2007) 0.95
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem (2007) 0.92
Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice. Neuropharmacology (2009) 0.92
Nicotine physical dependence in the mouse: involvement of the alpha7 nicotinic receptor subtype. Eur J Pharmacol (2005) 0.92
Environmental enrichment during development decreases intravenous self-administration of methylphenidate at low unit doses in rats. Behav Pharmacol (2012) 0.91
Synthesis and pharmacological characterization of exo-2-(2'-chloro-5-pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as novel epibatidine analogues. J Med Chem (2005) 0.91
SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav (2006) 0.91
Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol (2006) 0.91
Exposure to marijuana smoke impairs memory retrieval in mice. J Pharmacol Exp Ther (2007) 0.91
Social facilitation of d-amphetamine self-administration in rats. Exp Clin Psychopharmacol (2011) 0.90
Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther (2004) 0.90
Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity. Pharmacology (2002) 0.89
High impulsivity in rats predicts amphetamine conditioned place preference. Pharmacol Biochem Behav (2011) 0.89
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists. J Nat Prod (2010) 0.89
Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids. J Anal Toxicol (2012) 0.89
Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun (2005) 0.88
Structure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinols. Bioorg Med Chem (2003) 0.88
Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. Exp Neurol (2007) 0.88
In vivo characterization of a novel inhibitor of CNS nicotinic receptors. Eur J Pharmacol (2005) 0.86
Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res (2009) 0.86
Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther (2006) 0.86
A translational behavioral model of mood-based impulsivity: Implications for substance abuse. Drug Alcohol Depend (2011) 0.85
Hijacking of Basic Research: The Case of Synthetic Cannabinoids. Methods Rep RTI Press (2011) 0.85
1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg Med Chem (2002) 0.84
Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain (2007) 0.84
Antinociceptive effects of supraspinal rat cart (55-102) peptide in mice. Brain Res (2003) 0.84
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol (2006) 0.83
Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. Bioorg Med Chem (2006) 0.83
Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther (2002) 0.82
Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur J Pharmacol (2003) 0.82
Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. Eur J Pharmacol (2004) 0.80
Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem (2007) 0.80
Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. Eur J Pharmacol (2012) 0.80
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Bioorg Med Chem Lett (2007) 0.80
Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. Psychopharmacology (Berl) (2007) 0.79